CTLA4 and non-small cell lung carcinoma: To confirm the compound inhibitory effects on ICIs, we further checked if the compounds had a significant negative correlation (p < 0.05, R < 0, Pearson’s correlation test) between drug concentration and mRNA or protein expression of major ICIs for NSCLC treatment, including CD27, CTLA4, PD1 (PDCD1), and PDL1 (CD274) in the CCLE NSCLC cell lines (n = 135).